全文获取类型
收费全文 | 2101102篇 |
免费 | 163812篇 |
国内免费 | 9721篇 |
专业分类
耳鼻咽喉 | 28820篇 |
儿科学 | 64420篇 |
妇产科学 | 57259篇 |
基础医学 | 304941篇 |
口腔科学 | 58361篇 |
临床医学 | 197590篇 |
内科学 | 397448篇 |
皮肤病学 | 41625篇 |
神经病学 | 171234篇 |
特种医学 | 80229篇 |
外国民族医学 | 539篇 |
外科学 | 304356篇 |
综合类 | 62916篇 |
现状与发展 | 17篇 |
一般理论 | 716篇 |
预防医学 | 174571篇 |
眼科学 | 47765篇 |
药学 | 158027篇 |
61篇 | |
中国医学 | 8549篇 |
肿瘤学 | 115191篇 |
出版年
2021年 | 17414篇 |
2019年 | 17548篇 |
2018年 | 23881篇 |
2017年 | 18773篇 |
2016年 | 20411篇 |
2015年 | 24329篇 |
2014年 | 33645篇 |
2013年 | 50061篇 |
2012年 | 68805篇 |
2011年 | 72520篇 |
2010年 | 43652篇 |
2009年 | 40021篇 |
2008年 | 66062篇 |
2007年 | 69955篇 |
2006年 | 69535篇 |
2005年 | 67326篇 |
2004年 | 64126篇 |
2003年 | 61435篇 |
2002年 | 59196篇 |
2001年 | 89240篇 |
2000年 | 90799篇 |
1999年 | 76380篇 |
1998年 | 22658篇 |
1997年 | 20728篇 |
1996年 | 20245篇 |
1995年 | 19142篇 |
1994年 | 18068篇 |
1992年 | 61929篇 |
1991年 | 60640篇 |
1990年 | 59151篇 |
1989年 | 56394篇 |
1988年 | 52636篇 |
1987年 | 51584篇 |
1986年 | 49102篇 |
1985年 | 47184篇 |
1984年 | 35998篇 |
1983年 | 30791篇 |
1982年 | 18945篇 |
1979年 | 34459篇 |
1978年 | 24713篇 |
1977年 | 20535篇 |
1976年 | 19636篇 |
1975年 | 20579篇 |
1974年 | 25403篇 |
1973年 | 24636篇 |
1972年 | 23128篇 |
1971年 | 21520篇 |
1970年 | 20147篇 |
1969年 | 19021篇 |
1968年 | 17568篇 |
排序方式: 共有10000条查询结果,搜索用时 218 毫秒
11.
12.
Syed M. Gilani Muhammad Khan Andrea Barbieri Manju L. Prasad 《Diagnostic Histopathology》2021,27(6):263-271
Anaplastic thyroid carcinoma (ATC) is an aggressive thyroid malignancy with high mortality rate. This malignancy arises in thyroid follicular cells either denovo or with an associated differentiated thyroid carcinoma component. Clinically, it usually presents as a rapidly enlarging mass, pain and locally compressive symptoms. Histopathologic variability and heterogeneity often pose diagnostic challenges, especially in scant and paucicellular specimens. This article describes the clinical, histopathologic and molecular features of ATC and also addresses the associated diagnostic limitations and challenges. 相似文献
13.
Qian Zhang Larry D. Mesner Gina M. Calabrese Naomi Dirckx Zhu Li Angela Verardo Qian Yang Robert J. Tower Marie-Claude Faugere Charles R. Farber Thomas L. Clemens 《The Journal of clinical investigation》2021,131(7)
Bone mineral density (BMD) is a highly heritable predictor of osteoporotic fracture. GWAS have identified hundreds of loci influencing BMD, but few have been functionally analyzed. In this study, we show that SNPs within a BMD locus on chromosome 14q32.32 alter splicing and expression of PAR-1a/microtubule affinity regulating kinase 3 (MARK3), a conserved serine/threonine kinase known to regulate bioenergetics, cell division, and polarity. Mice lacking Mark3 either globally or selectively in osteoblasts have increased bone mass at maturity. RNA profiling from Mark3-deficient osteoblasts suggested changes in the expression of components of the Notch signaling pathway. Mark3-deficient osteoblasts exhibited greater matrix mineralization compared with controls that was accompanied by reduced Jag1/Hes1 expression and diminished downstream JNK signaling. Overexpression of Jag1 in Mark3-deficient osteoblasts both in vitro and in vivo normalized mineralization capacity and bone mass, respectively. Together, these findings reveal a mechanism whereby genetically regulated alterations in Mark3 expression perturb cell signaling in osteoblasts to influence bone mass. 相似文献
14.
15.
Hannah C. Nordhues Anjali Bhagra Natya N. Stroud Jennifer A. Vencill Carol L. Kuhle 《Mayo Clinic proceedings. Mayo Clinic》2021,96(7):1907-1920
The coronavirus disease 2019 (COVID-19) pandemic has rapidly created widespread impacts on global health and the economy. Data suggest that women are less susceptible to severe illness. However, sex-disaggregated data are incomplete, leaving room for misinterpretation, and focusing only on biologic sex underestimates the gendered impact of the pandemic on women. This narrative review summarizes what is known about gender disparities during the COVID-19 pandemic and the economic, domestic, and health burdens along with overlapping vulnerabilities related to the pandemic. In addition, this review outlines recommended strategies that advocacy groups, community leaders, and policymakers should implement to mitigate the widening gender disparities related to COVID-19. 相似文献
16.
17.
18.
Heather L. Brown 《Journal of emergency nursing》2021,47(2):321-325
The coronavirus 2019 pandemic has affected almost every aspect of health care delivery in the United States, and the emergency medicine system has been hit particularly hard while dealing with this public health crisis. In an unprecedented time in our history, medical systems and clinicians have been asked to be creative, flexible, and innovative, all while continuing to uphold the important standards in the US health care system. To continue providing quality services to patients during this extraordinary time, care providers, organizations, administrators, and insurers have needed to alter longstanding models and procedures to respond to the dynamics of a pandemic. The Emergency Medicine Treatment and Active Labor Act of 1986, or EMTALA, is 1 example of where these alterations have allowed health care facilities and clinicians to continue their work of caring for patients while protecting both the patients and the clinicians themselves from infectious exposures at the same time. 相似文献
19.
目的 运用CT区分脾脏血管性病变与淋巴瘤。方法 回顾性分析20例经手术、穿刺病理学检查证实的脾脏病变的发病年龄、性别、脾脏指数、病变大小、数目、有无液化、钙化、强化幅度、强化方式等特征,并进行统计学分析。结果 20例脾脏病变中,11例血管性病变(6例海绵状血管瘤,3例窦岸细胞血管瘤,2例硬化性血管瘤样结节性转化),9例淋巴瘤;两组间发病年龄、病变大小、数目、有无液化、钙化等差异无统计学意义;两组间脾脏指数、动脉期强化幅度差异具有统计学意义(P<0.05)。5例海绵状血管瘤呈不均匀性强化,1例呈渐进性填充式强化,2例窦岸细胞血管瘤呈“雀斑征”,1例硬化性血管瘤样结节性转化呈“辐轮征”;9例淋巴瘤实质部分均呈均匀、轻中度强化。结论 脾脏血管性病变与淋巴瘤CT表现不同,CT有助于明确诊断。 相似文献
20.
Melanie A. Krook Julie W. Reeser Gabrielle Ernst Hannah Barker Max Wilberding Gary Li Hui-Zi Chen Sameek Roychowdhury 《British journal of cancer》2021,124(5):880
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human cancers, although this frequency increases to 10–30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges associated with the development of clinical-grade molecular diagnostic tests to accurately detect these alterations in the tissue and blood of patients. The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-molecule inhibitors, as well as monoclonal antibodies against the receptors. We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, respectively. However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients. This phenomenon underscores the need to clearly delineate tumour-intrinsic and tumour-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.Subject terms: Cancer, Cancer 相似文献